Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody against phosphatidylserine (PS) with vascular targeting and immunomodulatory properties. It can reactivate anti-tumor immunity to inhibit tumor growth. Bavituximab has anti-cancer activity and is often used in combination with Paclitaxel and Carboplatin to study non-small cell lung cancer.

Bavituximab通过血清蛋白β2-糖蛋白1(β2GP1)结合至暴露的磷脂酰丝氨酸(PS)分子[1]。Bavituximab通过与PS结合诱导抗体依赖的细胞毒性，导致肿瘤血管的破坏[1]。在10μM索拉非尼作用下诱导暴露PS的情况下，Bavituximab（10 μg/mL; 48 h）能够结合至HUVEC和bEnd.3细胞中的PS[2]。

Sorafenib在小鼠肿瘤模型中诱导阴离子磷脂的外露。随后，Bavituximab（100 μg/只小鼠；静脉注射；单剂量；Sorafenib处理后48小时给药）可检测到体内磷脂酰丝氨酸的外露[2]。